A new HIV prevention drug, Lenacapavir, will be available at a significantly reduced cost of $40 in over 100 low- and middle-income countries by 2027, down from $28,000 annually. This injectable treatment, which has shown promising trial results and received WHO backing, aims to enhance access for vulnerable populations and replace existing daily oral PrEP medications.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
